A direct comparison of oral treatments with BAY-n-7133, BAY-1-9139 and ketoconazole in experimental murine coccidioidomycosis.
Two new experimental antifungal azole drugs were compared with ketoconazole for the management of experimental murine coccidioidomycosis. The first, BAY-n-7133, a triazole, was superior to the second, BAY-1-9139, an imidazole derivative. Neither BAY drug was as effective as ketoconazole in early fulminant coccidioidomycosis of mice, in later disseminated disease and in deep-seated chronic disease. A possible limitation of BAY-n-7133 in the mouse model was its reported capacity to induce enzyme changes that accelerated its clearance from serum. Induction of such an enzyme response in human beings has been reported not to occur.
D000284:Administration, Oral; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D055598:Chemical Phenomena; D002621:Chemistry; D003045:Coccidioides / Q000187:drug effects; D003047:Coccidioidomycosis / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007654:Ketoconazole / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D013172:Spores, Fungal / Q000187:drug effects; D014230:Triazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000935:Antifungal Agents; D007093:Imidazoles; D014230:Triazoles; C038973:BAY-i 9139; C037494:vibunazole; D007654:Ketoconazole